Evidence map›Paper›PMID 15371515›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2004

Glucagon-like peptide 1 excites hypocretin/orexin neurons by direct and indirect mechanisms: implications for viscera-mediated arousal.

Claudio Acuna-Goycolea, Anthony van den Pol

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 126 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Claudio Acuna-GoycoleaDepartment of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Anthony van den Pol
Yale University · US

Funding

Hypocretin NeuronsR01NS041454 · NINDS · YALE UNIVERSITY · PI VAN DEN POL, ANTHONY N · 2002 to 2010
$2.9M
GABA: EXCITATORY TRANSMITTER IN DEVELOPING HYPOTHALAMUSR01NS034887 · NINDS · YALE UNIVERSITY · PI VAN DEN POL, ANTHONY N · 1995 to 2008
$2.6M
NPY DEPRESSION OF HIPPOCAMPAL EPILEPSYR01NS037788 · NINDS · YALE UNIVERSITY · PI VAN DEN POL, ANTHONY N · 1999 to 2002
$909k
NINDS NIH HHS NS34887NINDS NIH HHS NS37788NINDS NIH HHS NS41454NINDS NIH HHS R01 NS034887NINDS NIH HHS R01 NS037788NINDS NIH HHS R01 NS041454
6 · The paper itself

Abstract

Glucagon-like peptide 1 (GLP-1) is produced by neurons in the caudal brainstem that receive sensory information from the gut and project to several hypothalamic regions involved in arousal, interoceptive stress, and energy homeostasis. GLP-1 axons and receptors have been detected in the lateral hypothalamus, where hypocretin neurons are found. The electrophysiological actions of GLP-1 in the CNS have not been studied. Here, we explored the GLP-1 effects on GFP (green fluorescent protein)-expressing hypocretin neurons in mouse hypothalamic slices. GLP-1 receptor agonists depolarized hypocretin neurons and increased their spike frequency; the antagonist exendin (9-39) blocked this depolarization. Direct GLP-1 agonist actions on membrane potential were abolished by choline substitution for extracellular Na+, and dependent on intracellular GDP, suggesting that they were mediated by sodium-dependent conductances in a G-protein-dependent manner. In voltage clamp, the GLP-1 agonist Exn4 (exendin-4) induced an inward current that reversed near -28 mV and persisted in nominally Ca2+-free extracellular solution, consistent with a nonselective cationic conductance. GLP-1 decreased afterhyperpolarization currents. GLP-1 agonists enhanced the frequency of miniature and spontaneous EPSCs with no effect on their amplitude, suggesting presynaptic modulation of glutamate axons innervating hypocretin neurons. Paraventricular hypothalamic neurons were also directly excited by GLP-1 agonists. In contrast, GLP-1 agonists had no detectable effect on neurons that synthesize melanin-concentrating hormone (MCH). Together, our results show that GLP-1 agonists modulate the activity of hypocretin, but not MCH, neurons in the lateral hypothalamus, suggesting a role for GLP-1 in the excitation of the hypothalamic arousal system possibly initiated by activation by viscera sensory input.

Indexed as

Action PotentialsAfferent PathwaysAnimalsArousalCholineDigestive SystemEatingExenatideGenes, ReporterGlucagonGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlutamic AcidHypothalamic HormonesHypothalamusIntracellular Signaling Peptides and ProteinsCholineExenatideexendin (9-39)Glp1r protein, mouseGlucagonGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlutamic AcidHypothalamic HormonesIntracellular Signaling Peptides and Proteinsmelanin-concentrating hormoneMelaninsNeuropeptidesOrexin ReceptorsOrexinsPeptide FragmentsPeptidesPituitary HormonesProtein PrecursorsReceptors, GlucagonReceptors, G-Protein-CoupledReceptors, NeuropeptideSodium Channel BlockersTetrodotoxinVenoms

Identifiers

PMID15371515
PMCPMC6729787
OpenAlexW2046431610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.